-The Hindu The disease cannot be eliminated without universal access to affordable, quality diagnostics and drugs After decades spent battling the scourge of tuberculosis (TB) in developing countries, 2018 might be the year that it is finally accorded the gravitas it deserves. On September 26, the UN General Assembly will, for the first time, address TB in a High-Level Meeting and likely release a Political Declaration, endorsed by all member nations, to...

-The Hindu Health protection scheme for 10.74 crore beneficiary families and 50 crore Indian citizens The healthcare sector has welcomed Prime Minister Narendra Modi’s announcement in his Independence Day address that the Pradhan Mantri Jan Arogya Abhiyaan, also known as Ayushman Bharat or the National Health Protection Mission (AB-NHPM), will be launched on September 25. The government-sponsored health insurance scheme will provide free coverage of up to ?5 lakh a family a year...

-The Telegraph New Delhi: Patients' rights advocates in India on Tuesday filed two oppositions in the Indian patent office, challenging patent claims by the US pharmaceutical company Gilead Sciences for its medicines sofosbuvir and velpatasvir, used to treat hepatitis-C infections. The oppositions filed by the Delhi Network of Positive People (DNP+) challenge Gilead's patent applications for the tablet formulations of the fixed dose combination of sofosbuvir and velpatasvir and a new form...

-The Indian Express The Department of Industrial Policy and Promotion (DIPP) and the NPPA are also documented as having given similar assurances in subsequent meetings. New Delhi: After the National Pharmaceutical Pricing Authority (NPPA) imposed price caps on coronary stents in February last year, the Prime Minister’s Office (PMO) is documented as having “indicated” to representatives of foreign medical device companies in a meeting that the Indian government has no plans to...

-The Telegraph New Delhi: A five-judge Supreme Court constitution bench on Wednesday ruled that parliamentary standing committee reports can be examined by courts for evidence evaluation, rejecting the Centre's argument that it would be a breach of parliamentary privileges and an encroachment into the domain of the legislature. The apex court, however, said "admissibility of a parliamentary committee report in evidence does not mean facts stated in the report stand proved", as...